Abstract：Nonalcoholic fatty liver disease (NAFLD), a clinical metabolic stress-induced liver injury, is expressed as a feature of intrahepatic cell steatosis and excessive fatty deposition. NAFLD is a rising cause of common chronic liver disease worldwide. However, due to the lack of idealized NAFLD experimental models, the pathogenesis of NAFLD remains to be elucidated and consequently the research and development of therapeutic drugs against NAFLD has been making a relatively slow progress. Therefore, the establishment of cell and animal models is of great significance for exploring its pathogenesis and screening relevant experimental drugs. In this paper, the experimental models involved in NAFLD are reviewed and its advantages and disadvantages are evaluated further in vitro and in vivo, which provides a sufficient theoretical basis and model selection for the investigation and development of innovative drugs against NAFLD.
BRUNT E M, WONG V W, NOBILI V, et al. Nonalcoholic fatty liver disease[J]. Nat Rev Dis Primers, 2015, 1:15080.
[2]
ARAB J P, ARRESE M, TRAUNER M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease[J]. Annu Rev Pathol, 2018, 13:321-350.
[3]
FRIEDMAN S L, NEUSCHWANDER_TETRI B A, RINELLA M, et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med, 2018, 24:908-922.
[4]
YE P, XIANG M, LIAO H, et al. Dual-specificity phosphatase 9 protects against non-alcoholic fatty liver disease in mice via ASK1 suppression[J]. Hepatology, 2019,69(11):76-93.
[5]
WILLEBRORDS J, PEREIRA I V, MAES M, et al. Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research[J]. Prog Lipid Res, 2015, 59:106-125.
[6]
NATIONAL WORKSHOP ON FATTY LIVER AND ALCOHOLIC LIVER DISEASE, FATTY LIVER EXPERT COMMITTEE. Guideline of prevention and treatment for nonalcoholic fatty liver disease:a 2018 update[J]. J Mod Med Health, 2018, 34(5):641-649.
[7]
ANSTEE Q M, GOLDIN R D. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research[J]. Int J Exp Pathol, 2006, 87(1):1-16.
[8]
ZHOU Y, DING Y L, ZHANG J L, et al. Alpinetin improved high fat diet-induced non-alcoholic fatty liver disease (NAFLD) through improving oxidative stress, inflammatory response and lipid metabolism[J]. Biomed Pharmacother, 2018, 97:1397-1408.
[9]
FABBRINI E, SULLIVAN S, KLEIN S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic and clinical implications[J]. Hepatology, 2010, 51(3):679-689.
[10]
SEKIYA M, YAHAGI N, MATSUZAKA T, et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression[J]. Hepatology, 2003, 38(6):1529-1539.
[11]
TØIBØI K S, KRISTIANSEN M N, HANSEN H H, et al. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis[J]. World J Gastroenterol, 2018, 24(2):179-194.
[12]
SINGH D P, KHARE P, ZHU J, et al. A novel cobiotic-based preventive approach against high-fat diet-induced adiposity, nonalcoholic fatty liver and gut derangement in mice[J]. Int J Obes (Lond), 2016, 40(3):487-496.
[13]
LIEBER C S, LEO M A, MAK K M, et al. Model of nonalcoholic steatohepatitis[J]. Am J Clin Nutr, 2004, 79(3):502-509.
[14]
LAU J K, ZHANG X, YU J. Animal models of non-alcoholic fatty liver disease:current perspectives and recent advances[J]. J Pathol, 2017, 241(1):36-44.
[15]
TRAK-SMAYRA V, PARADIS V, MASSART J, et al. Pathology of the liver in obese and diabetic ob/ob and db/db mice fed a standard or high-calorie diet[J]. Int J Exp Pathol, 2011, 92(6):413-421.
[16]
FELLMANN L, NASCIMENTO A R, TIBIRICA E, et al. Murine models for pharmacological studies of the metabolic syndrome[J]. Pharmacol Ther, 2013, 137(3):331-340.
[17]
XIONG L, CHEN L, ZHANG L L. Mechanism of high glucose-induced hepatic steatosis[J].China Health Care Nutr(中国保健营养), 2013, 9:22-24.
[18]
YAN S Y. The biochemical mechanism studied on tetracycline-induced nonalcoholic fatty liver disease[D]. Changsha:Hunan Normal University, 2014.
[19]
ZHANG Z B. Effects and mechanisms of improvement of emodin on Simple hepatic steatosis of non-alcoholic fatty liver[D]. Nanjing:Nanjing University of Chinese Medicine, 2012.
[20]
SANTHEKADUR P K, KUMAR D P, SANYAL A J. Preclinical models of non-alcoholic fatty liver disease[J]. J Hepatol, 2018, 68(2):230-237.
[21]
HEIER E C, MEIER A, JULICH-HAERTEL H, et al. Murine CD103(+) dendritic cells protect against steatosis progression towards steatohepatitis[J]. J Hepatol, 2017, 66(6):1241-1250.
[22]
GIUSTO M, BARBERI L, DI S F, et al. Skeletal muscle myopenia in mice model of bile duct ligation and carbon tetrachloride-induced liver cirrhosis[J]. Physiol Rep, 2017, 5(7):e13153.
[23]
LIU Y, SONG H, WANG L, et al. Hepatoprotective and antioxidant activities of extracts from Salvia-Nelumbinis naturalis against nonalcoholic steatohepatitis induced by methionine- and choline-deficient diet in mice[J]. J Transl Med, 2014, 12:315.
[24]
CORBIN K D, ZEISEL S H. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression[J]. Curr Opin Gastroenterol, 2012, 28(2):159-165.
[25]
SAVARD C, TARTAGLIONE E V, KUVER R, et al. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis[J]. Hepatology, 2013, 57(1):81-92.
[26]
CHEN Y Z, CHEN C L, TIAN X, et al. Research advances in animal models based on the pathogenesis and treatment of nonalcoholic fatty liver disease[J]. J Clin Hepatol(临床肝胆病杂志), 2017, 33(12):2457-2461.
[27]
HANAFI M Y, ZAHER E L M, EL-ADELY S E M, et al. The therapeutic effects of bee venom on some metabolic and antioxidant parameters associated with HFD-induced non-alcoholic fatty liver in rats[J]. Exp Ther Med, 2018, 15(6):5091-5099.
[28]
HANDA P, MORGAN-STEVENSON V,MALIKEN B D, et al. Iron overload results in hepatic oxidative stress, immune cell activation, and hepatocellular ballooning injury, leading to nonalcoholic steatohepatitis in genetically obese mice[J]. Am J Physiol Gastrointest Liver Physiol, 2016, 310(2):117-127.
[29]
RINELLA M E, ELIAS M S, SMOLAK R R, et al. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet[J]. J Lipid Res, 2008, 49(5):1068-1076.
[30]
LEGRY V, VAN R D M, LAMBERT B, et al. Endoplasmic reticulum stress does not contribute to steatohepatitis in obese and insulin-resistant high-fat-diet-fed foz/foz mice[J]. Clin Sci (Lond), 2014, 127(7):507-518.
[31]
WANG Y L, LI J, LIU L J, et al. A cell model of nonalcoholic steatohepatitis induced by FFA:establishment and dynamic monitoring[J]. Chin J Integr Tradit West Med Liver Dis(中西医结合肝病杂志), 2013, 23(4):225-227.
[32]
DAI N, ZHOU P, ZHANG Y Y, et al. Effect of aloe-elodin on non-alcoholic steatohepatitis cells model[J]. J Jiangsu Univ (Med Ed)(江苏大学学报:医学版), 2014, 24(6):478-482.
[33]
BARNETT R. Liver cirrhosis [J]. Lancet, 2018, 392(10144):275.
[34]
JIANG T, WANG L, LI X, et al. Inositol-requiring enzyme 1-mediated endoplasmic reticulum stress triggers apoptosis and fibrosis formation in liver cirrhosis rat models[J]. Mol Med Rep, 2015, 11(4):2941-2946.
[35]
CAI Y, LU D, ZOU Y, et al. Curcumin protects against intestinal origin endotoxemia in rat liver cirrhosis by targeting PCSK9[J]. J Food Sci, 2017, 82(3):772-780.
[36]
AREZZINI B, LUNGHI B, LUNGARELLA G, et al. Iron overload enhances the development of experimental liver cirrhosis in mice[J]. Int J Biochem Cell Biol, 2003, 35(4):486-495.
[37]
ABDUL-HAMID M, AHMED R R, MOUSTAFA N, et al. The antifibrogenic effect of etanercept on development of liver cirrhosis induced by thioacetamide in rats[J]. Ultrastruct Pathol, 2017, 41(1):23-35.
[38]
ATARASHI M, IZAWA T, MORI M, et al. Dietary iron overload abrogates chemically-induced liver cirrhosis in rats[J]. Nutrients, 2018, 10(10):E1400.
[39]
VERBEKE L, MANNAERTS I, SCHIERWAGEN R, et al. FXR Agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis[J]. Sci Rep, 2016, 6:33453.
[40]
HARDY T, OAKLEY F, ANSTEE Q M, et al. Nonalcoholic fatty liver disease: pathogenesis and disease spectrum[J]. Annu Rev Pathol, 2016, 11:451-496.
[41]
MARENGO A, ROSSO C, BUGIANESI E. Liver cancer: connections with obesity, fatty liver, and cirrhosis[J]. Annu Rev Med, 2016, 67:103-117.
[42]
WOLF M J, ADILI A, PIOTROWITZ K, et al. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes[J]. Cancer Cell, 2014, 26(4):549-564.
[43]
REIBERGER T, CHEN Y, RAMJIAWAN R R, et al. An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis[J]. Nat Protoc, 2015, 10(8):1264-1274.
[44]
ALVAREZ-GARCIA V, TAWIL Y, WISE H M, et al. Mechanisms of PTEN loss in cancer: it′s all about diversity[J]. Semin Cancer Biol, 2019.
[45]
WATANABE S, HORIE Y, KATAOKA E, et al. Non-alcoholic steatohepatitis and hepatocellular carcinoma:lessons from hepatocyte-specific phosphatase and tensin homolog (PTEN)-deficient mice[J]. J Gastroenterol Hepatol, 2007, 22(suppl 1):96-100.
[46]
TSUCHIDA T, LEE Y A, FUJIWARA N, et al. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer[J]. J Hepatol, 2018, 69(2):385-395.
[47]
ASGHARPOUR A, CAZANAVE S C, PACANA T, et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer[J]. J Hepatol, 2016, 65(3):579-588.
[48]
KOHJIMA M, HIGUCHI N, KATO M, et al. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease[J]. Int J Mol Med, 2008, 21(4):507-511.
[49]
BATATINHA H A, LIMA E A, TEIXEIRA A A, et al. Association between aerobic exercise and rosiglitazone avoided the NAFLD and liver inflammation exacerbated in PPAR-alpha knockout mice[J]. J Cell Physiol, 2017, 232(5):1008-1019.
[50]
CANO A, BUQUE X, MARTINEZ-UNA M, et al. Methionine adenosyltransferase 1A gene deletion disrupts hepatic very low-density lipoprotein assembly in mice[J]. Hepatology, 2011, 54(6):1975-1986.
[51]
BYRNE C D, TARGHER G. NAFLD:a multisystem disease[J]. J Hepatol, 2015, 62(1):S47-S64.
[52]
COLE B K, FEAVER R E, WAMHOFF B R, et al. Non-alcoholic fatty liver disease(NAFLD) models in drug discovery[J]. Expert Opin Drug Discov, 2018, 13(2):193-205.
[53]
ROTMAN Y, SANYAL A J. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease[J]. Gut, 2017, 66(1):180-190.
[54]
QIANG X, XU L, ZHANG M, et al. Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress[J]. Biochem Biophys Res Commun, 2016, 472(4):603-609.
2019, Vol. 54 
